At a Glance
- Company: BioNTech (Nasdaq: BNTX)
- Location: Mainz, Germany
- Headline figures: Shares -20%; new co. gets mRNA IP license
- Focus area: Next-gen mRNA innovations
- Next steps: Binding agreement by June; CEO search underway
What happened?
BioNTech announced on 10 March 2026 that co-founders CEO Ugur Şahin and CMO Özlem Türeci will leave by year-end to establish a new mRNA-focused company. BioNTech will license next-gen mRNA technologies to the startup on arm’s-length terms for equity stake, milestones and royalties.
Why does it matter?
Şahin and Türeci built BioNTech into a COVID vaccine powerhouse (Comirnaty with Pfizer) valued at $25B+ peak; their exit amid oncology focus shift injects leadership uncertainty despite mature pipeline. New venture targets disruptive mRNA beyond BioNTech’s commercial stage. Shares fell 20%.
Who’s behind it?
BioNTech co-founders Şahin/Türeci pioneered mRNA; board initiates CEO/CMO search. New entity operates independently with separate funding.
How was it achieved?
Mutual agreement transfers mRNA IP rights for minority stake/royalties; BioNTech retains cancer/COVID assets unaffected. Founders depart post-transition.
What’s next?
Binding licence by June 2026; BioNTech advances late-stage oncology while successors stabilise operations. New startup pioneers early-stage mRNA.
What are people saying?
Şahin: “Ready to become pioneers again.” Leerink: “Logical… but injects uncertainty.”